Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises EQT IX in connection with the acquisition of Parexel
Mandate

Vinge advises EQT IX in connection with the acquisition of Parexel

December 14, 2021 EU, Competition and Regulatory

Vinge has advised EQT IX on the merger control aspects of EQT IX’s and Goldman Sachs Asset Management’s acquisition of Parexel from Pamplona Capital Management for USD 8.5 billion.

Parexel carries out biopharmaceutical outsourcing services providing a comprehensive suite of Phase I to IV solutions to the world’s biopharmaceutical companies. The acquisition was notified to a number of competition authorities worldwide including to the European Commission. Vinge’s team consisted primarily of Emma Johansson, Johan Wahlbom, Victoria Fredén and Jesper Ekman.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026